SALE
市場調查報告書
商品編碼
1021836

中樞神經系主導療藥的市場預測、競爭趨勢、成長機會 (∼2026年):各醫藥品分類、用途、給藥途徑、終端用戶、通路、地區

Global Central Nervous System Therapeutics Market, By Drug Class, By Application, By Route of Administration, By End User, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2026

出版日期: | 出版商: TechSci Research | 英文 118 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

  • 全貌
  • 簡介
  • 目錄
簡介

全球中樞神經系主導療藥的市場規模從2020年的829億4746萬美元,在預測期間中預計以7.4%的年複合成長率成長。

有效的治療計劃和更好藥物的需求擴大,來自海外的直接投資增加等要素促進該市場的成長。

各醫藥品分類中,多發性硬化症治療藥的部門預計領導市場,成長率預計抗癲癇藥物部門將以更快的速度成長。還有各用途中,神經退化性疾病的部門2020年顯示整體34.29%的佔有率,在預測期間內預計該部門也維持優勢。

本報告提供全球中樞神經系主導療藥的市場調查,市場定義和概要,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,客戶的迴響分析,市場規模的變化、預測,各醫藥品分類、用途、給藥途徑、終端用戶、各銷售管道的明細,各地區、主要國家的詳細分析,競爭環境,主要企業簡介等彙整資訊。

第1章 產品概要

第2章 調查手法

第3章 COVID-19的影響

第4章 摘要整理

第5章 客戶的迴響

第6章 全球市場預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各醫藥品分類
      • 多發性硬化症
      • 抗精神病藥
      • 抗癲癇藥
      • 止痛藥、麻醉劑
      • 抗帕金森氏症
      • 其他
    • 各用途
      • 神經退化性疾病
      • 心理健康、外傷
      • 神經血管疾病
      • 感染疾病
      • CNS癌症
      • 其他
    • 各給藥途徑
      • 口服
      • 非口服
      • 其他
    • 各終端用戶
      • 醫院
      • 診療所
      • 診斷實驗室
      • 其他
    • 各銷售管道
      • 醫院藥局
      • 零售藥局
      • 線上藥局
    • 各企業
    • 各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東、非洲
  • 產品市場地圖

第7章 北美市場分析、預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各醫藥品分類
    • 各用途
    • 各給藥途徑
    • 各終端用戶
    • 各銷售管道
    • 各國
  • 各國分析

第8章 歐洲市場分析、預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各醫藥品分類
    • 各用途
    • 各給藥途徑
    • 各終端用戶
    • 各銷售管道
    • 各國
  • 各國分析

第9章 亞太地區市場分析、預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各醫藥品分類
    • 各用途
    • 各給藥途徑
    • 各終端用戶
    • 各銷售管道
    • 各國
  • 各國分析

第10章 南美市場分析、預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各醫藥品分類
    • 各用途
    • 各給藥途徑
    • 各終端用戶
    • 各銷售管道
    • 各國
  • 各國分析

第11章 中東、非洲市場分析、預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各醫藥品分類
    • 各用途
    • 各給藥途徑
    • 各終端用戶
    • 各銷售管道
    • 各國
  • 各國分析

第12章 市場動態

  • 促進因素
  • 課題

第13章 市場趨勢、市場展開

第14章 競爭情形

  • 競爭預測
  • 主要企業的簡介
    • Biogen Inc.
    • Johnson & Johnson
    • F. Hoffmann-La Roche AG
    • Novartis AG
    • Sanofi AG
    • Eli Lilly and Company Ltd.
    • Pfizer Inc.
    • Merck & Co. Inc.
    • AstraZeneca PLC
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline PLC
    • Bayer AG
    • Otsuka Holdings Co. Ltd.
    • Amgen Inc.
    • Bristol Myers Squibb Pharmaceuticals Ltd.

第15章 策略性建議

第16章 關於本公司、免責聲明

目錄
Product Code: 7322

Global Central Nervous System Therapeutics market was valued USD 82947.46 million in 2020 and is forecast to grow with an impressive CAGR of 7.4% in the forecast period. The market showed a steady growth in the historical years and is expected to continue to grow in the next five years too. The growth of the market can be attributed to the increasing demand for the effective treatment plans and better medication. Furthermore, the rising foreign direct investments are also contributing to the growth of the global central nervous system therapeutics market.

Global Central Nervous System Therapeutics market is segmented by drug class, application, route of administration, end user, distribution channels, and regional distribution and by company. Based on drug class the market is further fragmented into multiple sclerosis, antipsychotic, antiepileptics, analgesics & anesthetics, anti-Parkinson, and others. The multiple sclerosis sub-segment is expected to dominate the market in the future whereas antiepileptics is expected to grow at a faster rate.

The application segment is further fragmented into neurodegenerative diseases, mental health and trauma, neurovascular diseases, infectious diseases, CNS cancer and others. The neurodegenerative diseases sub-segment is dominating the Central Nervous System Therapeutics Market accounting for 34.29% of total market share in 2020. Over the forecast period, the category is expected to maintain its dominance. The rising incidence of neurodegenerative disorders such as Multiple Sclerosis, Alzheimer's and Parkinson's, as well as the high cost of treatment of these neurodegenerative disorders, are expected to boost the segmental share.

According to the Parkinson's Foundation, in United States alone, there were approximately 930,000 people suffering from Parkinson diseases in 2020 and it is estimated that by 2030, there will be around 1.2 million people in the United States with Parkinson disease. According to the National Council of Behavioral Health, approximately 70% of adults, in the United States will be exposed to some form of traumatic events once in their lifetime.

Future of the market is favorably dependent on the advancement of therapeutic drugs for central nervous system disorders. The market experiences a rising demand for effective drugs and motivating investments from pharmaceutical companies in research and development.

Some of the major players in the market are Biogen Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Novartis AG, Sanofi AG, Eli Lilly and Company Ltd., Pfizer Inc., Merck & Co. Inc., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Bayer AG, Otsuka Holdings Co. Ltd., Amgen Inc., Bristol Myers Squibb Pharmaceuticals Ltd. among others. The companies are focusing on extensive research and developments activities to stay competitive in the market. Other competitive strategies include formation of alliances and partnerships.

Years considered for this report:

Historical Years: 2016 - 2019

Base Year: 2020

Estimated Year: 2021

Forecast Period: 2022 - 2026

Objective of the Study:

  • To analyze the historical growth in the market size of Global central nervous system therapeutics market from 2016 to 2020.
  • To estimate and forecast the market size of Global central nervous system therapeutics market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast Global central nervous system therapeutics market based on drug class, application, route of administration, end User, distribution channel, and regional distribution.
  • To identify dominant region or segment in the Global central nervous system therapeutics market.
  • To identify drivers and challenges for Global central nervous system therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in Global central nervous system therapeutics market.
  • To identify and analyze the profile of leading players operating in Global central nervous system therapeutics market.
  • To identify key sustainable strategies adopted by market players in Global central nervous system therapeutics market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and distributors across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of Global central nervous system therapeutics market using a bottom-up approach, wherein data for various end-User segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Central nervous system therapeutics manufacturers, end user, distributors and other stakeholders
  • distributors and suppliers of central nervous system therapeutic drugs and other stakeholders
  • Organizations, forums, and alliances related to central nervous system therapeutics
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, end User, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, Global central nervous system therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Central Nervous System Therapeutics Market, By Drug Class:

Multiple Sclerosis

Antipsychotic

Antiepileptics

Analgesics & Anesthetics

Anti-Parkinson

Others

  • Global Central Nervous System Therapeutics Market, By Application:

Neurodegenerative Diseases

Mental Health and Trauma

Neurovascular Diseases

Infectious Diseases

CNS Cancer

Others

  • Global Central Nervous System Therapeutics Market, By Route of Administration:
  • Oral
  • Parenteral
  • Others
  • Global Central Nervous System Therapeutics Market, By End User:
  • Hospitals
  • Clinics
  • Diagnostic Laboratories
  • Others
  • Global Central Nervous System Therapeutics Market, By Distribution Channel:

Hospital Pharmacy

Online Pharmacy

Retail Pharmacy

  • Global Central Nervous System Therapeutics Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

APAC

  • China
  • Japan
  • India
  • South Korea
  • Australia

South America

  • Brazil
  • Argentina
  • Colombia

MEA

  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global central nervous system therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Central Nervous System Therapeutics Market

4. Executive Summary

5. Voice of Customer

  • 5.1. Factors Driving Global Central Nervous System Therapeutics Market
  • 5.2. Factors Influencing Purchase Decision of Central Nervous System Drugs
  • 5.3. Brand Awareness

6. Global Central Nervous System Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class (Multiple Sclerosis, Antipsychotic, Antiepileptics, Analgesics & Anesthetics, Anti-Parkinson, Others)
    • 6.2.2. By Application (Neurodegenerative Diseases, Mental Health and Trauma, Neurovascular Diseases, Infectious Diseases, CNS Cancer, Others)
    • 6.2.3. By Route of Administration (Oral, Parenteral, Others)
    • 6.2.4. By End User (Hospital, Clinics, Diagnostic Laboratories, Others)
    • 6.2.5. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
    • 6.2.6. By Company (2020)
    • 6.2.7. By Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa)
  • 6.3. Market Map

7. North America Central Nervous System Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Application
    • 7.2.3. By Route of Administration
    • 7.2.4. By End User
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country (United States; Canada; Mexico)
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Central Nervous System Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By End User
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. Canada Central Nervous System Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By End User
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. Mexico Central Nervous System Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By End User
        • 7.3.3.2.5. By Distribution Channel

8. Europe Central Nervous System Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Application
    • 8.2.3. By Route of Administration
    • 8.2.4. By End User
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country (Germany; France; United Kingdom; Italy; Spain)
  • 8.3. Europe: Country Analysis
    • 8.3.1. Germany Central Nervous System Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By End User
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. France Central Nervous System Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By End User
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. United Kingdom Central Nervous System Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By End User
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. Italy Central Nervous System Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By End User
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Spain Central Nervous System Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By End User
        • 8.3.5.2.5. By Distribution Channel

9. APAC Central Nervous System Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Application
    • 9.2.3. By Route of Administration
    • 9.2.4. By End User
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country (China; Japan; India; South Korea; Australia)
  • 9.3. APAC: Country Analysis
    • 9.3.1. China Central Nervous System Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By End User
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. Japan Central Nervous System Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By End User
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. India Central Nervous System Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By End User
        • 9.3.3.2.5. By Distribution Channel
    • 9.3.4. South Korea Central Nervous System Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Class
        • 9.3.4.2.2. By Application
        • 9.3.4.2.3. By Route of Administration
        • 9.3.4.2.4. By End User
        • 9.3.4.2.5. By Distribution Channel
    • 9.3.5. Australia Central Nervous System Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Class
        • 9.3.5.2.2. By Application
        • 9.3.5.2.3. By Route of Administration
        • 9.3.5.2.4. By End User
        • 9.3.5.2.5. By Distribution Channel

10. South America Central Nervous System Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Application
    • 10.2.3. By Route of Administration
    • 10.2.4. By End User
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country (Brazil; Argentina; Colombia)
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Central Nervous System Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By End User
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Argentina Central Nervous System Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By End User
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. Colombia Central Nervous System Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Drug Class
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By Route of Administration
        • 10.3.3.2.5. By End User
        • 10.3.3.2.6. By Distribution Channel

11. MEA Central Nervous System Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class
    • 11.2.2. By Application
    • 11.2.3. By Route of Administration
    • 11.2.4. By End User
    • 11.2.5. By Distribution Channel
    • 11.2.6. By Country (South Africa; Saudi Arabia; UAE)
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Central Nervous System Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Application
        • 11.3.1.2.3. By Route of Administration
        • 11.3.1.2.4. By End User
        • 11.3.1.2.5. By Distribution Channel
    • 11.3.2. Saudi Arabia Central Nervous System Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Application
        • 11.3.2.2.3. By Route of Administration
        • 11.3.2.2.4. By End User
        • 11.3.2.2.5. By Distribution Channel
    • 11.3.3. UAE Central Nervous System Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Class
        • 11.3.3.2.2. By Application
        • 11.3.3.2.3. By Route of Administration
        • 11.3.3.2.4. By End User
        • 11.3.3.2.5. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Global Players Profiled (Leading Companies)
    • 14.2.1. Biogen Inc.
    • 14.2.2. Johnson & Johnson
    • 14.2.3. F. Hoffmann-La Roche AG
    • 14.2.4. Novartis AG
    • 14.2.5. Sanofi AG
    • 14.2.6. Eli Lilly and Company Ltd.
    • 14.2.7. Pfizer Inc.
    • 14.2.8. Merck & Co. Inc.
    • 14.2.9. AstraZeneca PLC
    • 14.2.10. Teva Pharmaceutical Industries Ltd.
    • 14.2.11. GlaxoSmithKline PLC
    • 14.2.12. Bayer AG
    • 14.2.13. Otsuka Holdings Co. Ltd.
    • 14.2.14. Amgen Inc.
    • 14.2.15. Bristol Myers Squibb Pharmaceuticals Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Figures

  • Figure 1: Global Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 2: Global Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 3: Global Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 4: Global Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 5: Global Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 6: Global Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 7: Global Central Nervous System Therapeutics Market Share, By Company, 2016-2026F
  • Figure 8: Global Central Nervous System Therapeutics Market Share, By Region, By Value, 2016-2026F
  • Figure 9: Global Central Nervous System Therapeutics Market Size, Market Map, By Value, 2016-2026F
  • Figure 10: North America Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 11: North America Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 12: North America Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 13: North America Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 14: North America Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 15: North America Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 16: North America Central Nervous System Therapeutics Market Share, By Country, By Value, 2016-2026F
  • Figure 17: United States Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 18: United States Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 19: United States Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 20: United States Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 21: United States Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 22: United States Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 23: Canada Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 24: Canada Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 25: Canada Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 26: Canada Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 27: Canada Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 28: Canada Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 29: Mexico Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 30: Mexico Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 31: Mexico Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 32: Mexico Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 33: Mexico Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 34: Mexico Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 35: Europe Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 36: Europe Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 37: Europe Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 38: Europe Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 39: Europe Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 40: Europe Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 41: Europe Central Nervous System Therapeutics Market Share, By Country, By Value, 2016-2026F
  • Figure 42: Germany Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 43: Germany Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 44: Germany Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 45: Germany Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 46: Germany Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 47: Germany Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 48: France Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 49: France Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 50: France Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 51: France Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 52: France Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 53: France Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 54: United Kingdom Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 55: United Kingdom Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 56: United Kingdom Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 57: United Kingdom Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 58: United Kingdom Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 59: United Kingdom Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 60: Italy Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 61: Italy Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 62: Italy Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 63: Italy Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 64: Italy Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 65: Italy Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 66: Spain Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 67: Spain Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 68: Spain Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 69: Spain Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 70: Spain Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 71: Spain Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 72: APAC Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 73: APAC Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 74: APAC Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 75: APAC Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 76: APAC Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 77: APAC Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 78: APAC Central Nervous System Therapeutics Market Share, By Country, By Value, 2016-2026F
  • Figure 79: China Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 80: China Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 81: China Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 82: China Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 83: China Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 84: China Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 85: Japan Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 86: Japan Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 87: Japan Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 88: Japan Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 89: Japan Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 90: Japan Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 91: India Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 92: India Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 93: India Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 94: India Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 95: India Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 96: India Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 97: South Korea Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 98: South Korea Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 99: South Korea Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 100: South Korea Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 101: South Korea Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 102: South Korea Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 103: Australia Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 104: Australia Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 105: Australia Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 106: Australia Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 107: Australia Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 108: Australia Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 109: South America Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 110: South America Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 111: South America Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 112: South America Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 113: South America Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 114: South America Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 115: South America Central Nervous System Therapeutics Market Share, By Country, By Value, 2016-2026F
  • Figure 116: Brazil Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 117: Brazil Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 118: Brazil Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 119: Brazil Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 120: Brazil Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 121: Brazil Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 122: Argentina Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 123: Argentina Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 124: Argentina Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 125: Argentina Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 126: Argentina Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 127: Argentina Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 128: Colombia Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 129: Colombia Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 130: Colombia Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 131: Colombia Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 132: Colombia Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 133: Colombia Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 134: MEA Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 135: MEA Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 136: MEA Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 137: MEA Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 138: MEA Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 139: MEA Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 140: MEA Central Nervous System Therapeutics Market Share, By Country, By Value, 2016-2026F
  • Figure 141: South Africa Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 142: South Africa Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 143: South Africa Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 144: South Africa Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 145: South Africa Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 146: South Africa Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 147: Saudi Arabia Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 148: Saudi Arabia Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 149: Saudi Arabia Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 150: Saudi Arabia Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 151: Saudi Arabia Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 152: Saudi Arabia Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 153: UAE Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 154: UAE Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F
  • Figure 155: UAE Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 156: UAE Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F
  • Figure 157: UAE Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F
  • Figure 158: UAE Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F